| scholarly article | Q13442814 |
| P50 | author | Catherine M Sackley | Q56885782 |
| Bridget Penhale | Q59594654 | ||
| Carl E Clarke | Q63919326 | ||
| Helen Flaherty | Q64853924 | ||
| P2093 | author name string | Katherine H O Deane | |
| David J Daley | |||
| Roland Pascoe | |||
| Stacey Storey | |||
| P2860 | cites work | The COMET (Core Outcome Measures in Effectiveness Trials) Initiative: Its Role in Improving Cochrane Reviews | Q24199056 |
| Comparison of speech and language therapy techniques for speech problems in Parkinson's disease | Q24201335 | ||
| Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease | Q24201565 | ||
| Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease | Q24240186 | ||
| Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease | Q24242971 | ||
| Dopamine agonist therapy in early Parkinson's disease | Q24243105 | ||
| Occupational therapy for patients with Parkinson's disease | Q24243925 | ||
| Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease | Q24246072 | ||
| Protocol of the COSMIN study: COnsensus-based Standards for the selection of health Measurement INstruments | Q25257899 | ||
| Relation between agendas of the research community and the research consumer | Q33961168 | ||
| Anticholinergics for symptomatic management of Parkinson's disease | Q34205550 | ||
| Is society losing control of the medical research agenda? | Q34595580 | ||
| Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis. | Q36143500 | ||
| Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease | Q37012381 | ||
| Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease | Q37849251 | ||
| Balance and falls in Parkinson's disease: a meta-analysis of the effect of exercise and motor training. | Q37889787 | ||
| Systematic review on factors associated with medication non-adherence in Parkinson's disease. | Q38047675 | ||
| Prospective study of the impact of fear of falling on activities of daily living, SF-36 scores, and nursing home admission | Q38496813 | ||
| A meta-analysis of six prospective studies of falling in Parkinson's disease | Q40201100 | ||
| Origin and funding of the most frequently cited papers in medicine: database analysis | Q42623138 | ||
| Patient and public involvement in clinical trials | Q43167651 | ||
| Well informed uncertainties about the effects of treatments | Q43172971 | ||
| Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: a randomised controlled trial. | Q46328005 | ||
| Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial | Q50454449 | ||
| The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials | Q81065110 | ||
| Confronting therapeutic ignorance | Q81652777 | ||
| Prioritizing research: Patients, carers, and clinicians working together to identify and prioritize important clinical uncertainties in urinary incontinence | Q84578178 | ||
| The impact of occupational therapy in Parkinson's disease: a randomized controlled feasibility study | Q84587628 | ||
| Living with Parkinson's disease: priorities for research suggested by patients | Q87978001 | ||
| P433 | issue | 12 | |
| P921 | main subject | prioritization | Q11888847 |
| Parkinson's disease | Q11085 | ||
| research priority | Q119852497 | ||
| P304 | page(s) | e006434 | |
| P577 | publication date | 2014-12-14 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease | |
| P478 | volume | 4 |
| Q35605014 | A multi-centre, randomised controlled trial of the effectiveness of PDSAFE to prevent falls among people with Parkinson's: study protocol |
| Q59333168 | A protocol to evaluate the impact of involvement of older people with dementia and age-related hearing and/or vision impairment in a multi-site European research study |
| Q61797194 | Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial |
| Q36419572 | Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis |
| Q40283401 | Barriers and Facilitators for Participation in People with Parkinson's Disease. |
| Q57491499 | Beyond Dopamine: GABA, Glutamate, and the Axial Symptoms of Parkinson Disease |
| Q36538098 | Body-Worn Sensors in Parkinson's Disease: Evaluating Their Acceptability to Patients |
| Q41540738 | Cognitive Function in Parkinson's Disease Patients with and without Anxiety |
| Q36173068 | Defining Priorities for Future Research: Results of the UK Kidney Transplant Priority Setting Partnership |
| Q47740365 | Encoding strategy training and self-reported everyday prospective memory in people with Parkinson disease: a randomized-controlled trial |
| Q37744289 | Establishing a set of research priorities in care homes for older people in the UK: a modified Delphi consensus study with care home staff |
| Q37416255 | External validation of a 3-step falls prediction model in mild Parkinson's disease. |
| Q47378765 | Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort |
| Q47669727 | Increased odds of bladder and bowel symptoms in early Parkinson's disease |
| Q42358785 | Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET |
| Q57793188 | Lymphedema Research Prioritization Partnership: A Collaborative Approach to Setting Research Priorities for Lymphedema Management |
| Q92583570 | Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage? |
| Q92583327 | Outcome on Balance and Gait Following Botulinum Toxin Treatment for Striatal Foot in Parkinson's Disease |
| Q52677085 | Patient and public engagement in priority setting: A systematic rapid review of the literature. |
| Q92620876 | Patient and public involvement in dementia research in the European Union: a scoping review |
| Q36947405 | Patient involvement in research priorities (PIRE): a study protocol |
| Q37335240 | Patients' Views on a Combined Action Observation and Motor Imagery Intervention for Parkinson's Disease |
| Q47975880 | Patients' views on priority setting in neurosurgery: A qualitative study |
| Q38731344 | Potential of APDM mobility lab for the monitoring of the progression of Parkinson's disease |
| Q57797222 | Practice-based research agenda priorities selected by patients: findings from a dental practice-based research network |
| Q33617418 | Public priorities for osteoporosis and fracture research: results from a general population survey |
| Q35867684 | Qualitative evaluation of adherence therapy in Parkinson's disease: a multidirectional model. |
| Q47305047 | Rapid research and implementation priority setting for wound care uncertainties |
| Q91995417 | Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease |
| Q57924480 | Research priorities for managing the impacts and dependencies of business upon food, energy, water and the environment |
| Q90213987 | Research priorities in infertility and assisted reproductive technology treatments - a James Lind Alliance priority setting partnership with brazilian patients |
| Q47569789 | Research priority setting in Barrett's oesophagus and gastro-oesophageal reflux disease. |
| Q91986624 | Sensory focused exercise improves anxiety in Parkinson's disease: A randomized controlled trial |
| Q64799944 | The 10-year Landscape of United States-Registered Parkinson Disease Clinical Trials: 2007-2016 |
| Q47103772 | The Bright Elusive Butterfly of Value in Health Technology Development: Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies". |
| Q93038228 | The James Lind Alliance process approach: scoping review |
| Q92330790 | Top research priorities for preterm birth: results of a prioritisation partnership between people affected by preterm birth and healthcare professionals |
Search more.